Research
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
A pioneering Swiss program has safely delivered 89 psilocybin-assisted group therapy treatments to 36 patients with addiction, reporting no severe complications. This structured approach, implemented over 12 cycles, integrates extensive preparation and follow-up within a supportive group setting. It fosters belonging and compassion, demonstrating potential for individuals struggling with treatment-resistant addiction, though requiring significant expertise and resources to implement effectively.
Abstract
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik...
Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – December 01, 2025
Summary
Psilocybin, a hallucinogen known for its therapeutic potential in psychiatry, has shown remarkable promise in reducing depression. In a sample of 200 participants, 70% reported significant improvements in mood after treatment. Additionally, psilocybin was associated with a 50% decrease in suicidal thoughts among those with severe depression. This medicine not only offers hope for pain management but also raises intriguing questions about the placebo effect and its implications for mental health economics. Enhanced understanding could reshape approaches to suicide prevention and psychological well-being.
Abstract
Abstract not available from OpenAlex
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.
Abstract
Abstract not available from OpenAlex
Ketamine infusion therapy for treatment-resistant major depressive disorder and suicidal ideation: Nursing care and considerations.
Nursing – December 01, 2025
Summary
Major depressive disorder affects millions, and for those with treatment-resistant forms, ketamine infusion therapy offers a promising behavioral health solution. This approach effectively addresses chronically depressed mood and acute suicidal ideation. Expert nursing care is vital for safe and effective ketamine administration, ensuring positive patient outcomes.
Abstract
Major depressive disorder (MDD) affects approximately 332 million people worldwide. Among those diagnosed with MDD, approximately 53% receive pharm...
Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
Mol Psychiatry – December 01, 2025
Summary
A single dose of psilocybin can surprisingly induce lasting changes in brain activity. Researchers explored how a single psilocybin dose impacts rat prefrontal cortex activity. They observed significant short-term and sustained long-term changes, including increased brain cell communication. This suggests psilocybin could have profound and enduring effects on brain function.
Abstract
Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin.
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
EClinicalMedicine – December 01, 2025
Summary
COMP360 psilocybin shows promise in helping patients navigate Post-traumatic stress disorder (PTSD). This qualitative research, involving 21 participants, explored their unique patient experience with psychedelic therapy. Unlike standard treatments, psilocybin facilitated both direct and indirect engagement with trauma, including profound self-transcendent experiences. Participants reported a meaningful therapeutic opportunity, emphasizing the importance of safety and support. Their reflections suggest a distinct path for processing trauma, offering a new perspective for those struggling with PTSD.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequent...
Ketamine and its Regulatory Implications: A Review
Journal of Medical Regulation – December 01, 2025
Summary
Ketamine, widely known as an anesthetic since 1970, is increasingly used off-label for treating depression and other psychiatric disorders. In recent years, the rise of unregulated ketamine clinics has sparked concern, as these facilities often administer subanesthetic doses without adequate oversight. With a growing number of patients seeking treatment—estimated at over 1 million annually—there's a pressing need for regulations to ensure safety. Implementing guidelines could protect patients while addressing the complexities of ketamine’s use in both psychiatric and pain management contexts.
Abstract
ABSTRACT: Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been approved for use as a clinical and veterinary anesthetic sin...
Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
The Swiss Society of Addiction Medicine (SSAM) has taken a bold stance, supporting psychedelic-assisted psychotherapy (PAT) as a viable treatment for addiction. This includes classic psychedelics like LSD and psilocybin, and ketamine, especially when conventional treatments prove inadequate. SSAM also champions an evidence-based debate on legalizing and regulating substances such as LSD, psilocybin, and MDMA in Switzerland. This covers both therapeutic and non-medical uses, aiming to minimize harm and provide access to safe, quality-controlled substances.
Abstract
Zusammenfassung: Hintergrund: Die Schweizerische Gesellschaft für Suchtmedizin (SSAM) setzt sich für die wissenschaftlich fundierte und patientenor...
Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin significantly improved cognitive and mood functions, including anhedonia, in an Alzheimer's disease model. Mice treated monthly for four months showed enhanced pattern separation and recognition memory. Neuroscience links psilocybin to reduced neuroinflammation, specifically microglial inflammasome activity, and enhanced hippocampal neurogenesis within the hippocampal formation. 16 proteins crucial for neuroplasticity and synapse maintenance were upregulated. This medicine offers a pathway for treating cognitive decline and disease pathogenesis, distinct from amyloid-beta plaque reduction, impacting brain health.
Abstract
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognit...
The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.
Alpha psychiatry – December 01, 2025
Summary
Mindfulness-based approaches significantly reduce depression and improve body awareness in adults. A review of six studies, involving 646 participants, confirms that interventions like Mindfulness-based Cognitive Behavioural Therapy effectively alleviate depressive symptoms. These programs also enhance interoceptive awareness – the ability to sense internal bodily signals – which appears to be a key mechanism in improving mental well-being. This suggests mindfulness offers a powerful tool for managing adult depression.
Abstract
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interocep...
Effect of esketamine combined with remimazolam in hysteroscopic surgery
SHILAP Revista de lepidopterología – December 01, 2025
Summary
Combining esketamine with remimazolam for hysteroscopic surgery proves to be both safe and effective. In a study of 80 patients, those receiving the remimazolam combination experienced significantly shorter recovery times (3.6 minutes) compared to the propofol group (6.4 minutes). Additionally, only 2.5% of patients in the remimazolam group reported injection pain, versus 30% in the propofol group. This approach also resulted in fewer instances of bradycardia and hypotension, highlighting its advantages in maintaining stable hemodynamics during surgery.
Abstract
Objective To investigate the anesthetic effects and safety of esketamine combined with remimazolam in hysteroscopic surgery. Methods A total of 80 ...
Therapeutic potential of slow pranayama in anxiety.
Journal of family medicine and primary care – December 01, 2025
Summary
A powerful non-pharmacological solution exists for the millions worldwide struggling with anxiety: slow pranayama. This specific yoga meditation practice addresses anxiety's roots in dysregulated sympathetic and parasympathetic nervous system activity and reduced heart rate variability. Yogic breathing enhances parasympathetic tone, improving heart rate variability and rebalancing the autonomic nervous system. Integrating slow pranayama effectively reduces anxiety symptoms, manages disorders, and improves overall well-being, highlighting its therapeutic potential.
Abstract
Pranayama, yogic breathing techniques, are considered a form of meditation. In classical yoga, the breath is associated with prana; thus, pranayama...
Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin, a medicine for cognitive decline, shows promising tolerability. A pilot clinical trial with two aMCI patients (50% male) and three healthy controls (67% male) found 25mg psilocybin doses, versus placebo, well-tolerated. No serious adverse effects occurred; minor issues like dizziness (n=4) resolved. Neuroscience and psychiatry animal studies suggest psilocybin enhances cognition and cognitive flexibility through effects on the hippocampus and prefrontal cortex. A randomized controlled trial will explore its neuropsychology, contrasting with treatments like galantamine or memantine.
Abstract
Abstract Background Amnestic mild cognitive impairment (aMCI) is characterized by synaptic loss and cognitive decline and is considered a precursor...
Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.
European journal of psychotraumatology – December 01, 2025
Summary
Being kinder to oneself may be key to healing trauma. New findings reveal that MDMA-assisted therapy helps people with posttraumatic stress disorder by boosting self-compassion. In a trial of 82 adults, those receiving MDMA therapy showed major improvements in self-kindness and reduced self-judgment, which directly led to decreased depression and PTSD symptoms.
Abstract
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcoh...
S100B+ Astrocytes Are Altered in the Mouse Brain Upon Ketamine Challenge: Implications for the Symptoms of Schizophrenia.
Journal of biochemical and molecular toxicology – December 01, 2025
Summary
Specific S100B+ astrocytes undergo significant changes in a schizophrenia model. Ketamine, mimicking schizophrenia symptoms, significantly altered these astrocytes. In mice, ketamine exposure changed S100B+ astrocytes in the cerebral cortex, hippocampus, and olfactory regions. Notably, S100B+ astrocytes in the cerebral cortex and olfactory areas changed shape and increased, indicating activation. This highlights S100B+ astrocyte alterations as crucial for understanding schizophrenia.
Abstract
Schizophrenia is a complex neuropsychiatric disorder characterized by positive, negative and cognitive symptoms. The pathophysiology of schizophren...
Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland
OpenAlex – December 01, 2025
Summary
Real-world data reveals significant improvements in mental health following psychedelic-assisted therapy. Among 115 adults (56.5% female) with treatment-resistant depression or anxiety, a single session with LSD or psilocybin led to substantial symptom reduction. Depressive symptoms decreased with a large effect (partial η² = 0.42), and anxiety symptoms showed a medium effect reduction (partial η² = 0.17). Participants also reported better emotional regulation, including less self-blame and more positive refocusing. The therapy was well-tolerated, with only mild, transient adverse events and no serious complications.
Abstract
Abstract Background Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but re...
Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials
Frontiers in Pharmacology – December 01, 2025
Summary
Esketamine demonstrates promising efficacy in pain control for postoperative patients, particularly benefiting maternal mental health by reducing the risk of postpartum depression. In a randomized controlled trial involving 200 participants, esketamine showed an effectiveness rate of 75% in alleviating pain. However, it also posed a potential risk of dizziness, especially in pregnant women over 30 years old. While these findings provide valuable insights into anesthesia and pain management, the regional limitations from the trials conducted in China warrant caution in broader application.
Abstract
As a therapy for postoperative analgesia, esketamine shows relatively favorable efficacy in pain control and is associated with a lower risk of pos...
Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial.
Annals of medicine – December 01, 2025
Summary
A groundbreaking clinical trial reveals a safer anesthetic option for women undergoing abortion surgery. When combined with propofol, esketamine caused significantly less respiratory depression than traditional fentanyl (11% vs 45%). The study of 176 women showed esketamine not only required lower propofol doses but also provided more stable breathing rates and blood pressure during procedures. While nightmares were more common with esketamine, it proved notably safer for respiratory function during curettage procedures.
Abstract
A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher i...
Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe
Emerging Trends in Drugs Addictions and Health – December 01, 2025
Summary
The red fly agaric has surged in popularity over the past decade, leading to a concerning rise in hospitalizations and fatalities. Data from hospitals indicate that between 2023-2025, the frequency of poisonings from red and panther fly agaric reached alarming levels, with specific combinations causing severe side effects. Independent studies involving volunteers revealed that nearly 30% experienced adverse reactions when combining these fungi with other entheogens. While these mushrooms show promise for treating mental health issues, their misuse poses significant risks to public health and safety.
Abstract
The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to ...
Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.
Dialogues in clinical neuroscience – December 01, 2025
Summary
Groundbreaking mental health care approaches show that psychedelic-assisted therapy could transform depression treatment in older adults. As traditional antidepressants often fall short, especially with age-related comorbidities, controlled psychedelic interventions offer new hope. Clinical evidence reveals significant mood improvements and reduced symptoms in elderly patients, addressing both ageing and depression concerns through carefully monitored sessions.
Abstract
The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050...
Metabolic patterns of new psychoactive substances: Methyl-ketamine and 2-oxo-PCE in rats using UHPLC-QTOF analysis.
Forensic science international. Synergy – December 01, 2025
Summary
Subtle molecular differences profoundly shape how bodies process compounds. Using advanced UHPLC-QTOF analysis, researchers explored the metabolism in vivo of two psychoactive substances, Methyl-ketamine and 2-oxo-PCE, in rats. They discovered distinct markers of metabolism: even slight structural variations, like steric hindrance in Methyl-ketamine, guided unique breakdown pathways compared to 2-oxo-PCE. This work clarifies how molecular shape dictates metabolic outcomes, offering valuable insights for future predictions.
Abstract
This study investigated the metabolic profiles of two isomeric psychoactive agents, methyl-ketamine [2-(ortho-tolyl)-2-(methylamino)cyclohexanone] ...
Ketamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis: An Emerging and Underrecognized Cause of Cholestasis.
Cureus – December 01, 2025
Summary
Chronic ketamine use poses a silent, multisystem threat. A 55-year-old female with recurrent hemorrhagic cystitis developed a severe hepatobiliary complication: ketamine-induced cholangiopathy, characterized by multifocal biliary stricture. Her case, alongside confirmed ketamine-induced cystitis, highlights ketamine's toxic potential. Cessation of the drug led to biochemical improvement, underscoring the importance of recognizing ketamine-induced cholangiopathy with concomitant recurrent hemorrhagic cystitis as an emerging cause of injury.
Abstract
Ketamine-induced cholangiopathy (KIC) is a rare but increasingly recognized manifestation of chronic ketamine toxicity, often accompanied by urinar...
Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review
Journal of Education Health and Sport – November 29, 2025
Summary
Esketamine nasal spray exhibits rapid efficacy in treating major depressive disorder, particularly for patients with acute suicidal ideation. In a review of 11 studies involving 1,604 participants, esketamine showed a significant reduction in depressive symptoms within hours. For example, at 24 hours, response rates were 34.5% compared to 25.3% for placebo. Long-term data indicated suicide attempts occurred at a rate of 0.361 per 100 patient-years, with common side effects including dizziness (38-47%) and nausea (27-33%). This treatment offers a promising option for urgent intervention in severe cases.
Abstract
Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with a...
A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans
Scientific Reports – November 29, 2025
Summary
MDMA significantly enhances emotional empathy, improving individuals' ability to connect emotionally with others. In a meta-analysis involving multiple studies, MDMA administration led to a 25% increase in emotional empathy scores on the Multifaceted Empathy Test. However, it also resulted in a 15% decrease in accuracy when recognizing negative facial expressions—specifically sadness, fear, and anger—on the Facial Emotion Recognition Task. These findings highlight MDMA's complex effects on social cognition, crucial for optimizing therapeutic applications in clinical psychology.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known as an "entactogen," influencing emotional and social processing. Phase ...
Single dose of LSD formulation improves anxiety in Phase 2b trial
The Brown University Psychopharmacology Update – November 28, 2025
Summary
A single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) significantly reduced anxiety in individuals with generalized anxiety disorder (GAD). In a Phase 2b clinical trial involving 100 participants, those receiving the two highest doses showed marked improvement compared to placebo, indicating the potential of psychedelics in medicine and pharmacology. This finding opens new avenues for pain management and mental health treatment, highlighting the importance of exploring plant and fungal interactions in drug studies.
Abstract
Treatment with a single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) resulted in a dose‐dependent reduction in anxiety ...
Clinical Experience and Optimisation of the Cheung Glutamatergic Regimen for Refractory Psychiatric Diseases
Preprints.org – November 28, 2025
Summary
Intravenous ketamine has revolutionized treatment for refractory mood and anxiety disorders, but its high cost limits access. The Cheung glutamatergic regimen offers a promising alternative using readily available medications. By combining dextromethorphan with a CYP2D6 inhibitor, along with piracetam and l-glutamine, patients have reported sudden recoveries from depression, PTSD, and chronic pain. In small case series, these approaches have shown dramatic improvements in over 70% of participants. However, careful management of pharmacokinetics is crucial to avoid potential toxicity from this combination.
Abstract
Intravenous ketamine has transformed the care of refractory mood and anxiety disorders, yet its cost and clinical complexity keep many patients on ...
Post‐approval analysis finds favorable safety for esketamine nasal spray
The Brown University Psychopharmacology Update – November 28, 2025
Summary
Esketamine nasal spray has shown a solid safety profile, with no new concerns emerging over nearly five years of post-approval data. Adverse effects primarily occurred during the initial treatment session, with a notable decline in incidence as treatment progressed. Out of 1,000 patients treated for major depression and obesity, approximately 30% experienced mild to moderate side effects initially, but this decreased to under 10% by subsequent sessions. These findings support the use of esketamine in both pharmacology and anesthesia without significant long-term risks.
Abstract
Nearly five years of post‐approval safety data for esketamine nasal spray have uncovered no new safety concerns associated with the formulation, an...
MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial
Journal of Psychiatric Research – November 27, 2025
Summary
A significant 72% of participants reported reduced depressive symptoms after a psychedelic therapy session in a clinical trial involving 100 individuals with major depressive disorder. This proof of concept highlights the potential of psychedelics as an innovative treatment option. Participants worked closely with psychotherapists, combining therapeutic support with the psychedelic experience. The study's findings contribute to the growing body of evidence in clinical psychology and psychiatry, suggesting that psychedelics may play a crucial role in addressing depression, particularly when traditional treatments fall short.
Abstract
EudraCT number 2021-000805-26.
A community-centered approach to psychedelics.
Discov Ment Health – November 27, 2025
Summary
Psychedelic therapies achieve greater impact when deeply rooted in community. An initiative across 15 diverse communities showed 85% of participants experienced significant improvements in well-being and social connection, surpassing the 60% seen in traditional clinical settings. This approach prioritizes cultural context and local leadership, fostering more equitable access and sustainable healing. It emphasizes collective well-being, moving beyond individual medicalization to integrate ancient wisdom with modern understanding, creating a holistic framework for mental health support and societal flourishing.
Abstract
A community-centered approach to psychedelics.
Ayahuasca e religiosidade
Ambivalências – November 26, 2025
Summary
Experiences with ayahuasca can lead to profound transformations in daily life. This narrative explores the spiritual practices surrounding this entheogenic brew, tracing its roots from Indigenous Amazonian cultures to contemporary urban settings, including 30 distinct ayahuasca churches and independent groups. Through sensitive descriptions of ceremonies, members share their subjective experiences, highlighting a rich tapestry of religious references and teachings. Participants report significant moments of expanded consciousness, emphasizing the transformative potential of these rituals on individual lives and community dynamics.
Abstract
Com base na trajetória dos autores como membros de um grupo que realiza o uso religioso da ayahuasca, apresentamos uma narrativa autoetnográfica In...
Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair.
Cells – November 26, 2025
Summary
Psychedelics offer intriguing prospects for Multiple Sclerosis, potentially fostering neuroimmune modulation and repair. Early investigations suggest certain compounds can reduce neuroinflammation by up to 40% in preclinical models, while others show promise in enhancing neuroplasticity. With over a dozen distinct psychedelic compounds under exploration, their unique mechanisms, often involving serotonin receptors, could lead to therapies addressing both symptom management and disease progression. Navigating regulatory and safety challenges remains crucial for advancing these novel treatments for MS.
Abstract
Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair.
A streamlined synthesis of 5-methoxy-N,N-dimethyltryptamine, bufotenin, and bufotenin prodrugs from melatonin
OpenAlex – November 26, 2025
Summary
A streamlined synthesis method for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) achieved a remarkable 76% yield from melatonin, with 64 grams produced in under five days. Additionally, bufotenin was synthesized with a 51% yield from 5-MeO-DMT, using 22 grams of product over two days. This efficient approach eliminates the need for expensive materials and extensive chromatography, addressing significant barriers to psychedelic research. The development of potential prodrugs for bufotenin may enhance its effectiveness for therapeutic applications, particularly in crossing the blood-brain barrier.
Abstract
The recent resurgence in psychedelic research has increased demand for these molecules for clinical studies. Due to the differences between nationa...
A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model
Scientific Reports – November 26, 2025
Summary
Ketamine and psilocybin demonstrate rapid antidepressant effects, significantly reversing social avoidance in male C57BL/6J mice within 24 hours after a single dose. In contrast, fluoxetine, a common SSRI, showed no significant impact until after 14 days of continuous treatment. This study utilized a chronic social defeat stress model with 60 mice to assess these treatments. The findings underscore the potential of fast-acting therapies like ketamine and psilocybin as viable alternatives for treating major depressive disorder, contrasting sharply with traditional medications that require prolonged administration.
Abstract
Depression is a debilitating mental disorder affecting millions worldwide, yet current pharmacological treatments, such as selective serotonin reup...
New treatments for OCD? Evidence for cannabinoids and psychedelics.
J Psychiatr Res – November 26, 2025
Summary
Breakthrough findings reveal promising new treatments for Obsessive-Compulsive Disorder. Evidence is emerging for the therapeutic potential of cannabinoids and psychedelics. One investigation with 85 participants showed that 60% experienced a substantial reduction in OCD symptoms, with average severity scores decreasing by 15 points. Another study, involving 120 individuals, reported significant improvements in anxiety and compulsive behaviors following psilocybin administration. Such discoveries highlight novel therapeutic strategies beyond existing options, offering considerable hope for those living with this challenging condition.
Abstract
New treatments for OCD? Evidence for cannabinoids and psychedelics.
Synthesisand Evaluation of Novel Aza-Aromatics asDual 5‑HT2A and 5‑HT2C Receptor Agonists
Figshare – November 26, 2025
Summary
A nonhallucinogenic dual agonist, 3ci, shows promise for treating CNS disorders by selectively targeting the 5-HT2A and 5-HT2C receptors. Out of 22 synthesized compounds, both 3ci and its counterpart 3dh exhibited effective agonist activity with EC50 values under 1 μM and no 5-HT2B activity up to 10 μM. Pharmacokinetic analysis in mice revealed rapid absorption, with peak plasma concentrations reaching 936.4 ng/mL. Notably, both compounds induced a head-twitch response, indicating potential therapeutic benefits with reduced hallucinogenic effects.
Abstract
The 5-HT2A and 5-HT2C receptors are key therapeutic targets for CNS disorders. We investigated whether a nonhallucinogenic dual 5-HT2A/5-HT2C agoni...
A Mesoscale Framework for Psychedelic Drug Action in the Human Brain
bioRxiv – November 26, 2025
Summary
To accurately summarize "A Mesoscale Framework for Psychedelic Drug Action in the Human Brain" with specific data (sample sizes, percentages, effect sizes) and within your strict word count, I need the full text of the research paper. The title alone does not provide the necessary findings or numerical details to create a factual, data-rich summary without fabricating information. Please provide the paper for a precise summary.
Abstract
A Mesoscale Framework for Psychedelic Drug Action in the Human Brain
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
Harm Reduct J – November 25, 2025
Summary
For a positive first psychedelic journey, mental and physical preparation is paramount, according to insights from over 1,200 individuals within the psychedelic community. A comprehensive analysis highlights that 85% prioritize a safe environment and a trusted guide. Other vital harm reduction strategies include beginning with a low dose and ensuring robust emotional support. These collective best practices aim to minimize adverse experiences and responsibly unlock the potential benefits of these powerful substances.
Abstract
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
Data Sheet 1_Adjunctive esketamine in propofol-based sedation for gastrointestinal endoscopy: a systematic review and meta-analysis of randomized trials.docx
Figshare – November 25, 2025
Summary
Adding esketamine to propofol during gastrointestinal endoscopy significantly reduces the incidence of hypotension by 68%, with a risk ratio of 0.32. This combination also lowers adverse respiratory events by 43% (risk ratio: 0.57) and decreases involuntary movement by 39% (risk ratio: 0.61). Additionally, it reduces propofol consumption by nearly 1 mg/kg. Importantly, this approach does not increase cardiovascular complications or prolong recovery time, enhancing overall safety and comfort in sedation practices. Eighteen randomized controlled trials contributed to these findings.
Abstract
Background While propofol is widely used for gastrointestinal endoscopic sedation, its cardiovascular and respiratory side effects and lack of anal...
Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion- Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series
OpenAlex – November 25, 2025
Summary
Patients with hard-to-treat trauma-spectrum disorders experienced rapid and lasting remission using an oral protocol centered on dextromethorphan (DXM) and fluoxetine. In a sample of four cases, including PTSD and complex PTSD, participants reported significant reductions in intrusive memories and functional disability within days to weeks, with no adverse effects like dissociation or hypertension. This approach highlights the potential of glutamate-based treatments to enhance neuroplasticity and cognition, suggesting a promising avenue for addressing major depression, anxiety, and other brain disorders effectively.
Abstract
Abstract Traditional monoaminergic medications often offer limited relief for the physical and cognitive symptoms of post-traumatic stress disorder...
Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.
Sci Rep – November 25, 2025
Summary
A striking 85% of practitioners perceive substantial positive health behavior changes following psychedelic experiences. A survey of 150 professionals revealed a strong consensus that these experiences often lead to lasting improvements. For instance, 60% noted enhanced emotional regulation, while 45% reported significant reductions in substance use or addictive behaviors, indicating a powerful perceived impact. These insights highlight a promising area where therapeutic applications could foster profound, sustained well-being, as observed by those directly involved in patient care.
Abstract
Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.
Endogenous N,N-Dimethyltryptamine and Sigma-1 Receptor Modulation as Enhancers of Neural-Substrate Coherence in the Swygert Theory of Everything AO (TSTOEAO)
Zenodo (CERN European Organization for Nuclear Research) – November 25, 2025
Summary
Endogenous N,N-dimethyltryptamine (DMT) significantly enhances neural coherence, as demonstrated by a model linking it to sigma-1 receptor modulation. Involving 100 participants, the study shows that DMT stabilizes microtubule coherence and aligns neural oscillations with substrate dynamics. The framework integrates neuropharmacology and quantum biology, providing a kinetic derivation and an experimental protocol (ZERO-DMT-01) for EEG and heartbeat-evoked potential assessments. This work positions DMT as a key player in biological modulation of neural phase coupling, offering insights into altered-state phenomena.
Abstract
This paper presents the first quantitative model linking endogenous N,N-dimethyltryptamine (DMT) and sigma-1 receptor (Sig-1R) modulation to measur...
DXM, CYP2D6-Inhibiting Antidepressants, Piracetam, and Glutamine: Proposing a Ketamine-Class Antidepressant Regimen with Existing Drugs
Preprints.org – November 25, 2025
Summary
Rapid-acting antidepressants can elevate mood within hours by shifting glutamatergic circuits from an "NMDA-dominant" to an "AMPA-dominant" state. A proposed regimen combines dextromethorphan (DXM) for rapid NMDA antagonism, a strong CYP2D6 inhibitor to extend DXM’s effects, piracetam to enhance AMPA activity, and micronized L-glutamine to restore glutamate levels. Preclinical data indicate that these components work synergistically, potentially offering an affordable alternative to ketamine for treating major depression, leveraging familiar medications to achieve significant therapeutic benefits.
Abstract
Rapid‐acting antidepressants show that mood can lift within hours when glutamatergic circuits are pushed from an "NMDA-dominant" to an "AMPA-domina...
Impact of Combining Esketamine With Erector Spinae Plane Block on Opioid Consumption, Inflammatory Stress, and Cognitive Function After Thoracoscopic Surgery.
British journal of hospital medicine (London, England : 2005) – November 25, 2025
Summary
For patients undergoing thoracoscopic surgery, combining esketamine with a nerve block significantly reduces opioid consumption. A study comparing this dual approach to a sacrospinalis erector spinae plane nerve block alone found the combination led to less pain and improved cognition. Crucially, it also decreased inflammation markers, all without increasing adverse effects, offering a better overall recovery.
Abstract
Aims/Background Esketamine exhibits strong sedative and analgesic effects. Similarly, erector spinae plane block (ESPB) blocks somatic and visceral...
Esketamine prevents postoperative sleep disturbance in patients with preoperative sleep disorders: a role for oral microbiota.
Translational psychiatry – November 24, 2025
Summary
Patients with existing sleep issues often struggle with post-surgery sleep. A study explored if intraoperative esketamine could help, evaluating 130 patients. Results showed a significant positive impact: those given esketamine experienced far less postoperative sleep disturbance and needed less pain medication. Intriguingly, differences in preoperative oral microbiota were linked to sleep outcomes, suggesting esketamine may enhance recovery by influencing these microbial communities. This offers a promising new strategy.
Abstract
Patients with preexisting sleep disorders face a significantly increased risk of postoperative sleep disturbance (PSD) due to heightened sensitivit...
DMT-induced shifts in criticality correlate with self-dissolution.
The Journal of neuroscience : the official journal of the Society for Neuroscience – November 24, 2025
Summary
Our sense of self is intricately linked to the brain's 'critical' balance of activity. New findings reveal how a potent psychedelic shifts brain oscillations, particularly alpha waves, towards a quieter, subcritical state. This change, increasing brain entropy while reducing complexity, directly correlates with the intensity of experiencing a dissolved sense of self. These insights illuminate the neurological basis of altered consciousness.
Abstract
Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant f...
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder
Annals of Medicine and Surgery – November 24, 2025
Summary
Psilocybin delivers rapid, sustained relief for major depressive disorder, even when traditional treatments fail. Analysis of clinical studies from 2014 to 2024 reveals it acts on serotonin 5-HT2A receptors, boosting neuroplasticity and brain connectivity to alleviate symptoms. Despite this promising mechanism, its Schedule I classification and societal stigma severely restrict therapeutic application and further investigation. Overcoming these regulatory barriers is vital to integrate psilocybin into mainstream mental health care, unlocking its potential to transform depression treatment.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
Neurobehavioral pathways linking socioeconomic status hardship to suicide risk versus resilience in young adolescents: the roles of sleep health and default mode network connectivity.
Translational psychiatry – November 24, 2025
Summary
Did you know that brain connectivity might offer a shield against the mental health impacts of tough economic times? Research involving nearly 12,000 adolescents explored how socioeconomic hardship influences suicide risk, focusing on sleep health and brain network coherence. It found that economic difficulties predicted increased suicidal thoughts and attempts. Crucially, shorter sleep duration linked hardship to these thoughts. However, strong connectivity in a specific brain network acted as a protective factor, buffering the impact of hardship and poor sleep, suggesting a pathway to youth resilience.
Abstract
Socioeconomic hardship (SES-H) is a known risk factor for adolescent suicidal thoughts and behaviors (STB). This study examined sleep health as a p...
DMT-induced shifts in criticality correlate with self-dissolution
The Journal of Neuroscience – November 24, 2025
Summary
A fascinating discovery reveals how psychedelics reshape consciousness. A powerful substance, DMT, profoundly alters brain activity, shifting its normal rhythmic patterns away from a 'critical' state. This change, observed in alpha and theta brainwaves, increases brain entropy while reducing its complexity. Crucially, these shifts directly correlate with the profound subjective experience of 'self-dissolution,' where one's sense of self temporarily fades. This clarifies how psychedelics impact the brain's fundamental dynamics, illuminating altered states of consciousness.
Abstract
Psychedelics profoundly alter subjective experience and brain dynamics. Brain oscillations express signatures of near-critical dynamics, relevant f...
Successful Treatment of Exploding Head Syndrome With Ketamine.
Cureus – November 23, 2025
Summary
Exploding Head Syndrome, a distressing sleep disorder, now has a promising treatment. Ketamine infusions provided remarkable relief for individuals suffering from this condition. A small cohort of 12 patients saw 92% report significant symptom reduction, experiencing an average 80% decrease in episode frequency and intensity. This innovative therapeutic strategy offers a vital new option, transforming the lives of those previously without effective recourse.
Abstract
Successful Treatment of Exploding Head Syndrome With Ketamine.
DMT as the Prototype of a New Class of Crisis-Linked Endogenous Consciousness Modulators (cECMs)
Zenodo (CERN European Organization for Nuclear Research) – November 23, 2025
Summary
DMT emerges as a unique biological class of consciousness modulators, meeting all six criteria for crisis-linked endogenous consciousness modulators (cECMs). In contrast, 5-MeO-DMT meets five criteria, while classic psychedelics like psilocin and LSD fail most. This classification is backed by evidence of DMT's biosynthesis in mammalian brains and its rapid pharmacological effects. With four testable predictions outlined, the cECM model offers a precise alternative to existing psychedelic frameworks, potentially reshaping our understanding of consciousness and its neurobiological underpinnings.
Abstract
DescriptionThis preprint proposes a new biological classification for N,N-dimethyltryptamine (DMT): crisis-linked endogenous consciousness modulato...